Bioequivalence and Bioavability data analysis with crossover design (ABE)
A bioequivalence and bioavability data analysis tool including sample size estimation, noncompartmental analysis (NCA) and generalized linear model (GLM)

Average bioequivalence and bioavailability data analysis tool
An average bioequivalence (ABE) and bioavailability data analysis tool including sample size estimation, noncompartmental analysis (NCA) and ANOVA (lm) for a standard RT/TR 2-treatment, 2-sequence, 2-period, and balanced, cross-over design

An average bioequivalence (ABE) and bioavailability data analysis tool including sample size estimation, noncompartmental analysis (NCA) and ANOVA (lm) for a standard RT/TR 2-treatment, 2-sequence, 2-period, and cross-over design

R (>= 2.5.0), reshape, nlme, sciplot, plotrix

Hsin-ya Lee <hsinyalee@gmail.com>, Yung-jin Lee <mobilePK@gmail.com>
R (>= 2.5.0), reshape, nlme, sciplot, plotrix, ICSNP
An average bioequivalence (ABE) and bioavailability data analysis tool including sample size estimation,
noncompartmental analysis (NCA), ANOVA (lm) for a standard RT/TR 2x2x2 crossover design and linear mixed
effect model (lme of nlme) for a 2-treatment, 2-sequence, more than 2 periods (i.e. 2x2x3/2x2x4) replicate
design.

An average bioequivalence (ABE) and bioavailability data analysis tool including sample size estimation,
noncompartmental analysis (NCA), ANOVA (lm) for a standard RT/TR 2x2x2 crossover design and linear mixed
effect model (lme of nlme) for a 2-treatment, 2-sequence, with 2 periods or more (i.e. 2x2x3/2x2x4)
replicate design or 2-treatment, 2-sequence, 1-period parallel ABE study (2x2x1).

Hsin-ya Lee <hsinyalee@gmail.com>, Yung-jin Lee
<mobilePK@gmail.com>
R (>= 2.8.0), reshape, nlme, sciplot, plotrix, ICSNP
An average bioequivalence (ABE) and bioavailability data
analysis tool including sample size estimation,
noncompartmental analysis (NCA), ANOVA (lm) for a standard
RT/TR 2x2x2 crossover design and linear mixed effect model (lme
of nlme) for a 2-treatment, 2-sequence, with 2 periods or more
(i.e. 2x2x3/2x2x4) replicate design or a 2-treatment,
2-sequence, and 1-period parallel ABE study (2x2x1).